Autolus Therapeutics PLC (AUTL)
3.955
+0.02
(+0.64%)
USD |
NASDAQ |
May 15, 15:08
Autolus Therapeutics Cash from Operations (Quarterly): -24.83M for Dec. 31, 2023
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -24.83M |
| September 30, 2023 | -40.19M |
| June 30, 2023 | -38.15M |
| March 31, 2023 | -42.42M |
| December 31, 2022 | -14.57M |
| September 30, 2022 | -31.90M |
| June 30, 2022 | -30.81M |
| March 31, 2022 | -35.03M |
| December 31, 2021 | -9.158M |
| September 30, 2021 | -34.75M |
| Date | Value |
|---|---|
| June 30, 2021 | -36.61M |
| March 31, 2021 | -37.34M |
| December 31, 2020 | -27.73M |
| September 30, 2020 | -39.06M |
| June 30, 2020 | -26.93M |
| March 31, 2020 | -24.03M |
| December 31, 2019 | -33.27M |
| September 30, 2019 | -24.49M |
| June 30, 2019 | -17.21M |
| March 31, 2019 | -26.52M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
-42.42M
Minimum
Mar 2023
-9.158M
Maximum
Dec 2021
-29.92M
Average
-31.90M
Median
Sep 2022
Cash from Operations (Quarterly) Benchmarks
| Adaptimmune Therapeutics PLC | -14.68M |
| Biodexa Pharmaceuticals Plc | -- |
| NuCana PLC | 0.4825M |
| TC BioPharm (Holdings) PLC | -- |
| Mereo BioPharma Group PLC | -- |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -1.477M |
| Cash from Financing (Quarterly) | 0.023M |
| Free Cash Flow | -156.57M |
| Free Cash Flow Per Share (Quarterly) | -0.1511 |
| Free Cash Flow Yield | -22.76% |